LIDDS Stock Overview
A drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LIDDS AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.11 |
| 52 Week High | SEK 0.46 |
| 52 Week Low | SEK 0.082 |
| Beta | 0.18 |
| 11 Month Change | -5.80% |
| 3 Month Change | -24.64% |
| 1 Year Change | -36.06% |
| 33 Year Change | -99.04% |
| 5 Year Change | -99.34% |
| Change since IPO | -99.04% |
Recent News & Updates
Recent updates
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
May 26
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
Dec 15Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?
Jul 19Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation
Mar 08We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate
Nov 23
Shareholder Returns
| LIDDS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -24.1% | -5.8% | -2.1% |
| 1Y | -36.1% | 14.3% | 10.8% |
Return vs Industry: LIDDS underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: LIDDS underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| LIDDS volatility | |
|---|---|
| LIDDS Average Weekly Movement | 24.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: LIDDS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LIDDS's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1 | Mats Wiking | www.liddspharma.com |
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. The company's oncology pipeline in clinical development includes Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological conditions, such as breast cancer, head and neck cancer, and prostate cancer; and Nanoimod, a NanoZolid-formulated agatolimod, which is a toll-like receptor 9 (TLR9) agonist. The company was founded in 2003 and is based in Uppsala, Sweden.
LIDDS AB (publ) Fundamentals Summary
| LIDDS fundamental statistics | |
|---|---|
| Market cap | SEK 14.40m |
| Earnings (TTM) | -SEK 25.60m |
| Revenue (TTM) | SEK 17.00k |
846.9x
P/S Ratio-0.6x
P/E RatioIs LIDDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIDDS income statement (TTM) | |
|---|---|
| Revenue | SEK 17.00k |
| Cost of Revenue | SEK 4.88m |
| Gross Profit | -SEK 4.86m |
| Other Expenses | SEK 20.74m |
| Earnings | -SEK 25.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -28,594.12% |
| Net Profit Margin | -150,588.24% |
| Debt/Equity Ratio | 0% |
How did LIDDS perform over the long term?
See historical performance and comparison